Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

Abstract Background Fatigue was reported as the most common any-grade adverse event (18.3%), and the most common grade 3 or higher immune-related adverse event (irAE) (0.89%) in patients receiving PD-1/PD-L1 checkpoint inhibitors in clinical trial. Methods The aim of this retrospective multicenter s...

Full description

Bibliographic Details
Main Authors: Alessio Cortellini, Maria G. Vitale, Federica De Galitiis, Francesca R. Di Pietro, Rossana Berardi, Mariangela Torniai, Michele De Tursi, Antonino Grassadonia, Pietro Di Marino, Daniele Santini, Tea Zeppola, Cecilia Anesi, Alain Gelibter, Mario Alberto Occhipinti, Andrea Botticelli, Paolo Marchetti, Francesca Rastelli, Federica Pergolesi, Marianna Tudini, Rosa Rita Silva, Domenico Mallardo, Vito Vanella, Corrado Ficorella, Giampiero Porzio, Paolo A. Ascierto
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Journal of Translational Medicine
Subjects:
Fatigue
Cancer
Immune-related adverse events
IL-6
PD-1/PD-L1 inhibitors
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s12967-019-02132-x

Internet

http://link.springer.com/article/10.1186/s12967-019-02132-x

Similar Items